| Not Yet Recruiting | Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophi NCT07281547 | Mayo Clinic | Phase 4 |
| Withdrawn | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gyn NCT07226102 | City of Hope Medical Center | N/A |
| Not Yet Recruiting | Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer NCT07527143 | Mayo Clinic | — |
| Not Yet Recruiting | GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education NCT07279571 | University of Southern California | — |
| Enrolling By Invitation | GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer NCT07316361 | Biogenea Pharmaceuticals Ltd. | EARLY_Phase 1 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Not Yet Recruiting | Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases. NCT07267780 | National Cancer Institute, Naples | — |
| Recruiting | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors NCT07216105 | Fate Therapeutics | Phase 1 |
| Not Yet Recruiting | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer NCT07146919 | Centre Leon Berard | Phase 1 / Phase 2 |
| Recruiting | Molecular and ctDNA Characterization of High-Risk Endometrial Cancer NCT07062016 | Mayo Clinic | — |
| Recruiting | Screening and Staging of Benign vs Malignant Pelvic Abnormalities NCT07407959 | Mayo Clinic | — |
| Not Yet Recruiting | Patient Journey in Advanced Gynecologic Cancers NCT07015593 | Tongji Hospital | — |
| Recruiting | An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in S NCT06855706 | Roswell Park Cancer Institute | N/A |
| Recruiting | Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of G NCT06632431 | Assiut University | — |
| Recruiting | First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab NCT06502743 | Yonsei University | Phase 2 |
| Not Yet Recruiting | Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatmen NCT06102252 | Sohag University | N/A |
| Recruiting | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic NCT06253494 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer NCT06413992 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier NCT06365905 | Mayo Clinic | — |
| Unknown | Study and Transformation of Tumor Molecular Features Screening Model of Endometrial Carcinoma Surgical Approac NCT05894915 | Peking University People's Hospital | N/A |
| Recruiting | FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 | Parabilis Medicines, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metast NCT05712941 | EQRx International, Inc. | Phase 3 |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Recruiting | A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer NCT05691010 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Recruiting | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Se NCT05256225 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma NCT05316467 | Xiaojun Chen | Phase 2 / Phase 3 |
| Unknown | The Clinical Significance of Sentinel Lymph Node Imaging Combined With Imaging Examination in Pelvic and Perit NCT03877627 | Second Affiliated Hospital of Wenzhou Medical University | N/A |
| Recruiting | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in NCT05078047 | UNICANCER | Phase 3 |
| Completed | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Usin NCT06789224 | Lindis Bloodcare GmbH | N/A |
| Unknown | A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment NCT05121363 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Active Not Recruiting | Targeting Inflammation for Endometrial Cancer Prevention NCT05407025 | Mayo Clinic | — |
| Active Not Recruiting | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer NCT04576104 | Northwestern University | Phase 2 |
| Active Not Recruiting | Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer NCT05139368 | University of Utah | N/A |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Terminated | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma NCT05036681 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444 | Guardant Health, Inc. | — |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or E NCT04839614 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma NCT04716686 | Shandong University | Phase 2 |
| Active Not Recruiting | Endometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy) NCT06790004 | Azienda USL Reggio Emilia - IRCCS | — |
| Active Not Recruiting | Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiatio NCT04713618 | Ohio State University Comprehensive Cancer Center | — |
| Active Not Recruiting | GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab NCT04652076 | NETRIS Pharma | Phase 1 / Phase 2 |
| Recruiting | Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer NCT04567771 | Mayo Clinic | N/A |
| Terminated | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer NCT04159155 | University Health Network, Toronto | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma NCT04251416 | Yale University | Phase 2 |
| Active Not Recruiting | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (K NCT04152499 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior NCT04178460 | Zai Lab (Shanghai) Co., Ltd. | Phase 1 |
| Completed | Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates NCT04474184 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors NCT04634617 | M.D. Anderson Cancer Center | — |
| Unknown | The Application of Real-Time Near-infrared Imaging in Gynecological Surgery NCT04224467 | Chen Chunlin | N/A |
| Completed | Trial of Maintenance With Niraparib- Uterine Serous Carcinoma NCT04080284 | Northwell Health | Phase 2 |
| Completed | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives NCT04257045 | M.D. Anderson Cancer Center | — |
| Suspended | Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial Carcinoma NCT03945786 | Xuanwu Hospital, Beijing | — |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Completed | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398 | Xencor, Inc. | Phase 1 |
| Active Not Recruiting | Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer NCT04678414 | M.D. Anderson Cancer Center | — |
| Completed | UTOLA: UTerin OLAparib NCT03745950 | ARCAGY/ GINECO GROUP | Phase 2 |
| Active Not Recruiting | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hyster NCT03671811 | City of Hope Medical Center | Phase 2 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Completed | Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivo NCT03372720 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care NCT03460483 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivor NCT03367923 | Stanford University | Phase 2 |
| Completed | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepitheli NCT03300557 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study of Nivolumab in Selected Uterine Cancer Patients NCT03241745 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight NCT03027479 | University Hospital, Tours | N/A |
| Unknown | A Study Evaluating MM-310 in Patients With Solid Tumors NCT03076372 | Merrimack Pharmaceuticals | Phase 1 |
| Completed | First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targetin NCT02977195 | Centre Leon Berard | Phase 1 |
| Completed | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer NCT03015129 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer NCT02983279 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Withdrawn | Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With NCT03902379 | Rutgers, The State University of New Jersey | N/A |
| Completed | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies NCT02807844 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors NCT02611024 | PharmaMar | Phase 1 / Phase 2 |
| Unknown | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTO NCT02730923 | Centre Leon Berard | Phase 1 / Phase 2 |
| Completed | MK-3475 Immunotherapy in Endometrial Carcinoma NCT02630823 | Washington University School of Medicine | Phase 1 |
| Completed | Preoperative Olaparib Endometrial Carcinoma Study (POLEN) NCT02506816 | MedSIR | — |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or NCT02584478 | Advenchen Laboratories, LLC | Phase 3 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Improved Method of Detecting Cancer Metastases NCT02368067 | Southeastern Regional Medical Center | N/A |
| Completed | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies NCT02025985 | Karyopharm Therapeutics Inc | Phase 2 |
| Completed | Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma NCT02017353 | University Hospital, Gasthuisberg | Phase 2 |
| Completed | Gentle Yoga and Dietary Counseling in Improving Physical Function and Quality of Life in Stage I-II Endometria NCT02465541 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma NCT01455493 | Genentech, Inc. | Phase 2 |
| Completed | Correlation of Peritoneal Fluid CA-125 Levels With Postoperative Tumor Histology NCT04830332 | Erdemli State Hospital | N/A |
| Active Not Recruiting | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT01366144 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Trisenox® in Women With Metastatic Endometrial Cancer NCT01184053 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Letrozole as a Treatment of Endometrial Cancer NCT00997373 | University of California, Davis | N/A |
| Completed | Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors NCT00756847 | Sanofi | Phase 1 |
| Completed | Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persi NCT00729586 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer NCT00791635 | M.D. Anderson Cancer Center | — |
| Completed | Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy fo NCT00879359 | The Cleveland Clinic | Phase 2 |
| Completed | Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate NCT00483327 | NYU Langone Health | Phase 2 |
| Completed | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced C NCT00423254 | Mannkind Corporation | Phase 1 |
| Unknown | Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial Hyperp NCT01273636 | National Taiwan University Hospital | — |
| Completed | Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma NCT00165126 | Dana-Farber Cancer Institute | — |
| Completed | Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. NCT00334295 | AstraZeneca | Phase 2 |